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Abstract 
Of the two 
18
F-labeled PET ligands currently available to image metabotropic glutamate 
receptor 5 (mGluR5), [
18
F]FPEB is reportedly superior because [
18
F]SP203 undergoes 
glutathionlyation, generating [
18
F]-fluoride ion that accumulates in brain and skull. To allow 
multiple PET studies on the same day with lower radiation exposure, we prepared [
11
C]FPEB 
and [
11
C]SP203 from [
11
C]hydrogen cyanide and compared their abilities to accurately quantify 
mGluR5 in human brain, especially as regards radiometabolite accumulation. Genomic plot was 
used to estimate the ratio of specific-to-nondisplaceable uptake (BPND) without using a receptor 
blocking drug. Both tracers quantified mGluR5; however [
11
C]SP203, like [
18
F]SP203, had 
radiometabolite accumulation in brain, as evidenced by increased distribution volume (VT) over 
the scan period. Absolute VT values were ~30% lower for 
11
C-labeled compared to 
18
F-labeled 
radioligands, likely caused by the lower specific activities (and high receptor occupancies) of the 
11
C radioligands. The genomic plot indicated ~60% specific binding in cerebellum, which makes 
it inappropriate as a reference region. Whole-body scans performed in healthy subjects 
demonstrated a low radiation burden typical for 
11
C-ligands. Thus, the evidence suggests that 
[
11
C]FPEB is superior to [
11
C]SP203. If prepared in higher specific activity, [
11
C]FPEB would 
presumably be as effective as [
18
F]FPEB for quantifying mGluR5 in human brain. 
 
Keywords: FPEB, genomic plot, mGluR5, SP203, PET imaging 
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Introduction 
Two 
18
F-labeled radioligands, FPEB and SP203, have been reported as high performing 
radioligands to measure metabotropic glutamate receptor 5 (mGluR5) in human brain; of these, 
[
18
F]FPEB
1, 2
 is clearly superior to [
18
F]SP203.
3, 4
 Although both radioligands have high brain 
uptake and relatively fast washout that allows quantitation of mGluR5s with compartmental 
modeling, [
18
F]SP203 has two limitations compared to [
18
F]FPEB. First, [
18
F]SP203 is 
metabolized in vivo with subsequent uptake of the
 
radiometabolites into bone, including skull, 
which spills over and contaminates adjacent neocortex.
2, 5
 Second, the apparent distribution 
volume (VT) of [
18
F]SP203 gradually increases during the scan, consistent with the accumulation 
of radiometabolites. Previous studies from our laboratory found that [
18
F]SP203 is metabolized 
in rat brain by glutathionylation, which generates [
18
F]fluoride ion that becomes trapped within 
brain due to poor ability to cross the blood-brain barrier (Fig. 1).
3, 6
 The apparent VT of 
[
18
F]SP203 increases about 10% per hour in human subjects. [
18
F]FPEB—currently the best 18F-
labeled radioligand for measuring mGluR5s—provides unusually stable measures of VT from 90 
to 360 minutes.
1
 
 Although the longer half-life of fluorine-18 allows distribution of radioligands to more 
distant PET centers, the shorter half-life and lower radiation exposure of carbon-11 allows 
multiple scans to be safely performed in the same subject on the same day. Such repeated 
administrations are particularly useful for studies that involve some intervention—e.g., 
measuring receptor occupancy before and after administration of a novel therapeutic. Here, we 
labeled FPEB and SP203 with carbon-11, each in the nitrile position. Thus, for each radioligand, 
the 
11
C- and 
18
F-labeled versions have the same chemical structure, but the radionuclide is on 
opposite sides of the molecule (Fig. 1).
7
 Part of the rationale for preparing [
11
C]SP203 was that 
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placing the radionuclide on the opposite end of the molecule from [
18
F]SP203 might avoid 
radiometabolite accumulation in brain. For example, if glutathionylation of [
11
C]SP203 occurs in 
human brain, the glutathionylated conjugate would likely be expelled from brain by multidrug 
resistance-associated protein 1 (MRP1) leaving only unchanged [
11
C]SP203 in brain.
8
 
The primary goals of this study were three-fold. First, we sought to compare [
11
C]FPEB 
and [
11
C]SP203 with regard to their ability to quantify mGluR5 in human brain by using 
radioligands with the same nuclidic label (i.e., 
11
C) and imaged for the same length of time (i.e., 
120 min) in order to reduce as many inherent differences as possible. Second, we measured time 
stability of VT to determine whether [
11
C]FPEB or [
11
C]SP203 generates radiometabolites that 
accumulate in brain, as indirectly shown by an apparent increase in VT during the course of the 
scan. Third, we sought to compare the two radioligands with regard to the ratio of specific to 
nondisplaceable uptake (i.e., BPND) as determined by genomic plot.
9, 10
 This plot is an adaptation 
of the Lassen/occupancy plot and correlates regional PET radioligand binding with the density of 
the cognate mRNA gene transcript. Similar to the Lassen/occupancy plot, the genomic plot 
allows extrapolation to an imaginary region lacking mRNA and receptors, which is the 
nondisplaceable uptake (VND) in brain. Unlike the Lassen/occupancy plot, the genomic plot does 
not use a receptor blocking drug. The secondary goal of this study was to estimate, based on 
whole body imaging, the radiation dosimetry of the two radioligands, given that they might be 
used in future human studies. 
 
Materials and Methods 
Chemistry 
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Materials and methods for chemistry, and description of the synthesis of precursor for labeling 
FPEB are contained in Supporting Information. 
 
Synthesis of [
11
C]FPEB. Radiosynthesis was performed within a modified
11
 remotely-controlled 
Synthia apparatus
12
 in a lead-shielded hot-cell for radiation protection (Supplementary Fig. 1). 
NCA [
11
C]hydrogen cyanide (~ 14 GBq) in nitrogen carrier gas was produced as 
described in Supporting Information and passed into a solution of KH2PO4 (2.5 mg) and 
kryptofix 2.2.2 (4 mg) in DMSO (0.30 mL) at ~ 300 mL/min, until the collected radioactivity 
reached a maximum. The reaction mixture was then heated to 80°C and purged with nitrogen at 
200 mL/min for one minute. Labeling precursor (0.6 mg) and tetra-
kis(triphenylphosphine)palladium(0) (0.5 mg) in DMSO (0.2 mL) were added to the reaction 
mixture, which was then sealed and heated at 80ºC for four minutes. The reaction mixture was 
then injected onto a Luna C18 column (5 µm, 10 mm × 250 mm, Phenomenex) eluted with a 
mixture (61: 39 v/v) of MeCN and aqueous TFA (0.1% w/v) at 6 mL/min, with eluate monitored 
for radioactivity and for absorbance at 254 nm. The fraction containing [
11
C]FPEB (tR=13.2 min) 
was collected. The incorporation of initial [
11
C]cyanide ion into [
11
C]FPEB was calculated from 
the radiochromatogram. The collected [
11
C]FPEB fraction was diluted in water (30 mL) and 
passed through a C18 cartridge (SepPak Plus; Waters Corp, Milford, MA). The cartridge was 
washed with water (10 mL) and eluted with dehydrated alcohol injection (USP, 2 mL) followed 
by 0.9% sodium chloride injection (USP, 2 mL). The combined eluent was passed through a 
sterile filter (Millex-MP, 0.22 µm, Millipore, Taunton, MA) into a sterile dose vial containing 
0.9% sodium chloride injection (USP, 16 mL) and measured for radioactivity. 
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Analysis of [
11
C]FPEB. The radiochemical purity, chemical purity, and specific activity of each 
batch of formulated [
11
C]FPEB were determined with HPLC on a Luna C18 column (10 µm, 4.6 
mm × 250 mm; Phenomenex) eluted at 3 mL/min with MeCN-10 mM HCOONH4 (45: 55 v/v) 
with column eluate monitored for radioactivity and absorbance at 254 nm ([
11
C]FPEB, tR=5.6 
min). The analytical method was calibrated for absorbance response (peak area) versus mass of 
injected FPEB to allow the amount of carrier FPEB in a known amount of [
11
C]FPEB to be 
measured, thereby giving the specific activity of the radioligand at the time of analysis. This 
value was corrected for radioactive decay to the end of synthesis. The identity of [
11
C]FPEB was 
also confirmed by LC-MS of the associated carrier. The radiochemical stability of formulated 
[
11
C]FPEB was checked by repeat HPLC analysis after the batch had been kept at room 
temperature for 60 minutes. 
 
Synthesis of [
11
C]SP203 
[
11
C]SP203 was labeled using an iodo precursor and [
11
C]cyanide ion as the labeling 
agent, as previously described.
7
 
 
Radioligand Preparation  
 
The radioligands were prepared according to our Investigational New Drug Application 
([
11
C]FPEB: 118,353, [
11
C]SP203: 105,222), which was submitted to the U.S. Food and Drug 
Administration; a copy is available at http://pdsp.med.unc.edu/snidd/. [
11
C]FPEB was obtained 
with high radiochemical purity (>99%) and specific activity of 22 ± 7 GBq/µmol at the time of 
injection (n=14 batches). [
11
C]SP203 was obtained with high radiochemical purity (>99%) and 
specific activity of 33 ± 11 GBq/µmol at the time of injection (n=14 batches).  
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Subjects 
 Approval for this study was obtained from the Institutional Review Board of the National 
Institute of Mental Health (NIMH), Ethics Committee and the Radiation Safety Committee of the 
National Institutes of Health (NIH). All the studies were conducted according to the Declaration 
of Helsinki. All subjects gave written informed consent. For [
11
C]FPEB, eight separate healthy 
volunteers participated in the brain PET scans (four males, four females; 28±8 years of age). Six 
separate healthy volunteers participated in the whole-body PET (n=4) or PET/CT (n=2) scans 
(three males, three females; 33±10 years of age). For [
11
C]SP203, six healthy volunteers 
participated in the brain positron emission tomography (PET) scans (three males, three females; 
30±12 years of age). Eight separate healthy volunteers participated in the whole-body 
PET/computed tomography (CT) scans (five males, three females; 32±9 years of age). All 
subjects were free of current medical or psychiatric illnesses as determined by medical history, 
physical examination, electrocardiogram (EKG), urinalysis, and laboratory blood tests (complete 
blood count, serum chemistries, and thyroid function test). The subject’s vital signs were 
recorded before radioligand injection and at 15, 30, 90, and 120 minutes after injection. Repeat 
urinalysis and blood tests were conducted within two hours of completing the PET scan.  
 
Brain PET 
Scan Procedure. Brain PET scans were performed on a GE Advance tomograph (GE Medical 
Systems, Waukesha, WI). [
11
C]FPEB (700 ± 24 MBq, n=8) or [
11
C]SP203 (649 ± 63 MBq; n=6) 
was intravenously injected over one minute and dynamic three-dimensional emission scans were 
acquired for 120 minutes in 33 frames of increasing duration from 30 seconds to five minutes. 
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One brain transmission scan using 
68
Ge rods was acquired before the injection of the radioligand. 
The position of the transmission scan was corrected for motion before applying attenuation 
correction. 
       
Measurement of [
11
C]FPEB and [
11
C]SP203 in Plasma. To determine arterial input function 
for brain PET scans, blood samples (1.5 mL each) were drawn from the radial artery at 15-
second intervals until 150 seconds, followed by 3 mL samples at 3, 4, 6, 8, 10, 15, 20, 30, 40, 
and 50 minutes, and 5 mL at 60, 75, 90, and 120 minutes. The concentration of parent 
radioligand was measured using HPLC as previously described.
13
 For [
11
C]FPEB the separation 
was done on preparatory X-Terra C18 column (10 µm, 7.8 x 300 mm; Waters Corp.) and a 
mobile phase of MeOH:H2O:Et3N (70:30:0.1, by volume). For [
11
C]SP203, the HPLC column 
used was Novapak C18 (100 x 8 mm; Waters Corp) with radial compression module RCM-100 
and a mobile phase of MeOH:H2O:Et3N (65:35:0.1, by volume). In addition, the plasma free 
fraction (fp) was measured by ultrafiltration, as previously described.
14
 
 
Blood Data Processing. The time-activity curves of parent [
11
C]FPEB or [
11
C]SP203 
concentrations were calculated by multiplying total plasma activity with fractions of [
11
C]FPEB 
or [
11
C]SP203 measured in plasma. Tri-exponential fitting was performed to the measured parent 
concentrations by weighting data according to errors in the measurement of each sample based 
on Poisson distribution. Whole blood radioactivity was used to correct radioactivity in brain that 
represents the vascular compartment (~5% of tissue volume).  
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Image Data Processing. Head movements were corrected after the scan by realigning all frames 
from each subject using Statistical Parametric Mapping, SPM (Version8 for Windows, 
Wellcome Department of Cognitive Neurology, UK). Brain regional data were obtained after 
coregistering magnetic resonance (MR) to PET images and spatial normalization to Montreal 
Neurologic Institute (MNI) space as previously described.
15
 The data were obtained in the 
following 10 volumes of interest (VOIs) in the MNI space: frontal (432 cm
3
), parietal (247 cm
3
), 
occipital (172 cm
3
), temporal (251 cm
3
), medial temporal (36 cm
3
), and cingulate (28 cm
3
) 
cortices; caudate (16 cm
3
); putamen (17 cm
3
); thalamus (17 cm
3
); and cerebellum (195 cm
3
). 
Image and kinetic analyses were performed using pixelwise modeling software (PMOD3.17, 
PMOD Technologies Ltd, http://www.pmod.com/). 
 
Calculating Distribution Volume (VT). The equilibrium value of VT was calculated three 
different ways to assess whether the methods applicable to voxel data yielded VT values similar 
to those obtained from VOI data using the gold standard method of compartmental modeling. 
 
Compartmental Modeling. Brain time-activity data were analyzed with compartmental 
modeling. Rate constants (K1, k2, k3, and k4) in standard one- and two-tissue compartment models 
were estimated with the weighted least-squares method and the Levenberg–Marquardt algorithm. 
Brain data for each frame were weighted by assuming that the standard deviation of the data was 
proportional to the inverse square root of noise equivalent counts. To correct brain data for the 
vascular component, radioactivity in serial whole blood was measured and subtracted from the 
PET measurements, assuming that cerebral blood volume is 5% of total brain volume. The delay 
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between the arrival of radioligand in the radial artery and brain was estimated by fitting the 
whole brain, excluding white matter.  
 
Linear and multilinear graphical analyses. The graphical approach of Logan
16
 was used to 
calculate VT. With the maximum deviation between the regression and all measurements set to 
20%, the equilibration start time (t*) and the slope of the linear portion of the Logan plot (VT) 
were fitted for each brain region that included data from multiple voxels within a VOI 
(LoganVOI). To decrease the bias induced by noise in the measurements, VT was also calculated 
by Ichise’s bilinear MA1 analysis,17 using the same t* obtained from the Logan analysis for each 
brain region (MA1VOI). 
 
Parametric modeling. To determine whether VT could be determined from the voxel data, 
parametric images of VT (Loganvoxel and MA1voxel) were generated using data from each voxel of 
dynamic PET images. For both Logan and MA1 methods, PET frames used for the regression 
were selected based on t* obtained from the time-activity curve of whole brain excluding white 
matter and by setting the maximum deviation between the regression and all measurements to 
20%. The same plasma input function as that used for compartmental modeling was used for the 
parametric modeling. After spatial normalization of the parametric images to the MNI space, VT 
values were obtained from the 10 regions described above to compare the results from kinetic 
analyses using the VOI data. 
 
Time-Stability Analysis. To determine the minimum scan length needed for reliable 
measurement, as well as to indirectly assess whether radiometabolites enter brain, the time 
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stability of VT was examined by increasingly truncating the scan duration from 0–120 minutes to 
0–30 minutes in 10-minute increments. 
 
Statistical Analysis 
 The optimal compartment model (i.e., one- vs. two-tissue compartment) was chosen 
based on the Akaike information criterion (AIC)
18
, model selection criterion (MSC) proposed by 
Micromath®, Saint Louis, MO, 
http://www.micromath.com/products.php?p=scientist&m=statistical_analysis), and F-test.
19
 The 
most appropriate model would be the one with the smallest AIC and the largest MSC value. F-
statistics were used to compare goodness-of-fit by one- and two-tissue compartment models. A 
value of p < 0.05 was considered significant. The identifiability (%) of rate constants was 
expressed as a percentage and equaled the ratio of the standard error (SE) of the kinetic variables 
divided by the value of the kinetic variables themselves. Identifiability (%) of VT was calculated 
from the covariance matrix using the generalized form of error propagation equation, where 
correlations among parameters (K1 and k2, or K1, k2, k3, and k4) were taken into account. A lower 
percentage indicates better identifiability.  
 For each subject, we used simple Logan and MA1 regression methods to compare 
regional brain VT values obtained from VOI and voxel data with VT values obtained from the 
two-tissue compartment model applied to VOI data. Differences in VT between methods were 
examined with repeated measures analyses of variance with region as the repeated factor. All 
statistical analyses were performed with SPSS (Version17 for Windows, SPSS Inc. Chicago, IL). 
Group data are expressed as mean±SD. The mean and SD for parametric images were calculated 
in each voxel across subjects. Values from all voxels were then averaged within each VOI. 
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Genomic Plot 
The genomic plot
9
 was used to compare [
11
C]FPEB and [
11
C]SP203 with regard to the 
ratio of specific to nondisplaceable uptake (i.e., BPND) without the use of a receptor blocking 
drug. The method is an adaption of the Lassen (or occupancy) plot
20
 and allows estimation of 
VND using the brain maps of mRNA transcripts of the target receptor as a surrogate measure of 
tracer-specific binding. 
The genomic plot was implemented as previously described.
9, 10
 Briefly, individual 
mRNA expression maps for mGluR5, as derived from the Allen Human Brain atlas 
(http://www.brain-map.org),
21
 were spatially normalized to the standard stereotaxic space 
(MNI/ICBM152). Based on their original anatomical labeling, the mRNA samples belonging to 
the same regions of interest (ROIs) were averaged across different donors.  
The regional mRNA measures for mGluR5 gene expression were then converted from 
log2 intensity into linear scale and linearly regressed with the population-average VT estimates 
for the corresponding ROIs for both PET tracers. The ROIs considered were: frontal, parietal, 
temporal and occipital lobes, cingulate gyrus, striatum, thalamus, and cerebellum. These regions 
were chosen to match the gene analysis with PET data quantification and to guarantee a 
sufficiently large number of samples per region (>10 per region and per donor). 
The squared Pearson’s correlation coefficient (R2) was used to quantify whether the 
relative gene transcript was proportional to VT. Following the assumption that mRNA expression 
can be used as a surrogate of tracer specific binding, VND was estimated as the x-intercept of the 
plot of mGluR5 transcript density vs. VT across brain regions. When specific binding is absent 
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(x-intercept), the value of VT equals VND. For both [
11
C]FPEB and [
11
C]SP203 the VND estimates 
were then used to calculate the tracer binding potentials (BPND=(VT/ VND -1)). 
 The processing of the mRNA data was done with MENGA (Multimodal Environment for 
Neuroimaging and Genomic Analysis),
22
 while genomic plot implementation was performed 
using Matlab®2012b (The MathWorks, Inc., Natick, MA) on a Windows 7 computer. 
 
Whole Body PET or PET/CT 
Scan Procedure. Whole-body PET scans were performed on an Advance tomograph (GE 
Medical Systems, Waukesha, WI) and whole-body PET/CT scans were performed on a Siemens 
Biograph
TM
 mCT (Siemens Healthcare, Malvern, PA). [
11
C]FPEB (547±210 MBq) or 
[
11
C]SP203 (633±125 MBq) was intravenously injected over 20 seconds, and dynamic three-
dimensional emission scans were acquired for ~120 minutes in 13 frames of increasing duration 
from 15 seconds to four minutes by serial imaging of the body from head to middle thigh in eight 
contiguous segments. One whole body 
68
Ge or CT transmission scan was used for attenuation 
correction. 
 
Dosimetry Analysis. Source organs were identified on the individual coronal slices of whole 
body PET/CT images. The frames with the highest organ uptake were averaged and smoothed by 
a Gaussian filter to increase the contrast between the organ and surrounding tissue. Brain, lungs, 
heart, liver, kidneys, gallbladder, urinary bladder, small intestine, lumbar vertebrae, and thyroid 
([
11
C]FPEB only) were identified as the source organs. 
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 Uptake in each source organ was corrected for recovery of measured activity, which was 
calculated by averaging the activity of the second through sixth frames where the image quality 
was good with a large ROI placed over the entire body visible by PET/CT.  
 At each time point, the activity not corrected for decay of the source organ was expressed 
as the fraction of the injected activity (IA). The area under the time-activity curve of each organ 
was calculated by the trapezoidal method until scan acquisition ended. The area after the last 
image to infinity was calculated by assuming that the subsequent decline of radioactivity 
occurred only via physical decay, without biological clearance. The area under the curve of 
percent IA from time zero to infinity equals the time-integrated activity coefficient, formerly 
known as “residence time” as per the 1991 Medical Internal Radiation Dose (MIRD) Primer of 
the organ (MIRD Pamphlet 21).
23
 The time-integrated activity coefficient of all red marrow in 
the body was estimated from that of the lumbar vertebrae as previously described.
5
 To calculate 
the time-integrated activity coefficient for the remainder of the body, the time-integrated activity 
coefficients for all of the source organs were summed and subtracted from the fixed theoretical 
value of t1/2/ln2=0.49 hours. 
 Radiation absorbed doses were calculated according to the MIRD scheme using 
OLINDA/EXM 1.1 (http://www.doseinfo-radar.com/OLINDA.html) and the model for a 70-kg 
adult male. 
 
Results 
Chemistry. The labeling of FPEB with carbon-11 was based on transition metal mediated aryl 
11
C-cyanation,
24 
and has been applied to the preparation of other mGluR receptor PET 
radioligands, such as [
11
C]SP203
7
 and [
11
C]AZD9272.
25
 Incorporation yields of [
11
C]FPEB 
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determined with HPLC were 47±7% (n=14). [
11
C]FPEB was obtained ready for intravenous 
administration in useful radiochemical yields of 2.5±0.7 GBq ( n=14). Single pass reverse phase 
HPLC afforded [
11
C]FPEB in high radiochemical purity (>99%), and in the absence of any 
significant chemical impurities. Formulated [
11
C]FPEB was stable when kept at room 
temperature for 60 minutes. 
 
Pharmacological Effects 
 The injected mass dose of [
11
C]FPEB (468±187 pmol/kg (n=14)) or [
11
C]SP203 
(296±108 pmol/kg (n=14)) caused no pharmacological or subjective effects in any subject during 
the two-hour PET scan. Specifically, it did not change blood pressure, pulse, respiratory rate, 
EKG, or pulse oximetry. Similarly, no significant effects were noted in any of the blood or urine 
tests acquired at the end of the scan.  
 
Plasma Analysis 
[
11
C]FPEB concentrations in arterial plasma peaked to 21±3 SUV at 1.3 minutes after 
injection and then rapidly declined, followed by a slow terminal clearance phase. The fitting of 
plasma parent curves converged by tri-exponential function in all subjects (Fig. 2A). The fraction 
of [
11
C]FPEB, expressed as a percentage of total plasma radioactivity, declined rapidly and 
reached 31±6% at 15 minutes, followed by a gradual decline (Fig. 2B). Radiometabolites 
appeared quickly in plasma and, after five minutes, became the predominant component of 
plasma radioactivity. Radiometabolites A–D eluted before the more lipophilic parent and were 
not well resolved among themselves by reverse-phase HPLC (Supplementary Fig. 2A). The fp of 
[
11
C]FPEB was 6.3±0.8% (n=8). 
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  [
11
C]SP203 concentrations in arterial plasma peaked to 15±3 SUV at 1.5 minutes after 
injection, and then rapidly declined, followed by a slow terminal clearance phase. The fitting of 
plasma parent curves converged by tri-exponential function in all subjects (Fig. 2D). The fraction 
of [
11
C]SP203, expressed as a percentage of total plasma radioactivity, declined rapidly and 
reached 12±5% at 15 minutes, followed by a gradual decline (Fig. 2E). Radiometabolites 
appeared quickly in plasma and, after five minutes, became the predominant component of 
plasma radioactivity. Radiometabolites A–D eluted before the more lipophilic parent and were 
not well resolved among themselves by reverse-phase HPLC (Supplementary Fig. 2B). A small 
peak, radiometabolite E, was seen just after the parent. The fp of [
11
C]SP203 was 2.8±0.1% (n=6). 
 
Brain Radioactivity and Kinetic Analysis 
After [
11
C]FPEB or [
11
C]SP203 injections, all subjects showed high concentrations of 
radioactivity followed by quick washout in all regions. [
11
C]FPEB radioactivity in brain peaked 
at 6.4±0.7 SUV (n=8) within 10 minutes and decreased to 52% of the peak by 120 minutes (Fig. 
2C). [
11
C]SP203 radioactivity in brain peaked at 5.5±1.0 SUV (n=6) within 10 minutes and 
decreased to 60% of the peak by 120 minutes (Fig. 2F). The regional distribution of radioactivity 
was consistent with the known distribution of mGluR5 in the human brain, with high levels in 
neocortex and striatum and lowest levels in cerebellum.
26
 
 Kinetic analysis of brain and plasma data for [
11
C]FPEB and [
11
C]SP203 had three major 
findings: 1) regional brain data were well fit by a two-tissue compartment model; 2) voxel-level 
data analyzed with a bilinear method (Ichise MA1) gave accurate values compared to those from 
regional analyses; and 3) the time stability of VT for [
11
C]FPEB was better than that for 
[
11
C]SP203. 
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 With regard to the first result, unconstrained two-tissue compartmental fitting converged 
in all regions and in all scans for both [
11
C]FPEB and [
11
C]SP203 (Figs. 2C and 2F). An F-test 
showed that the two-tissue compartment model was superior to the one-tissue compartment 
model in all 10 regions of all subjects for both radiotracers, consistent with the presence of 
significant amounts of both specific and nonspecific binding in human brain. In addition, the 
two-tissue compartment model showed lower mean AIC and higher mean MSC scores than the 
one-tissue compartment model. The unconstrained two-tissue compartment model identified VT 
with an average SE across brain regions of 0.6% for [
11
C]FPEB and 2.1% for [
11
C]SP203. 
Regional values of two-tissue mean VT (mL∙cm
-3
) for [
11
C]SP203 ranged from 26 in temporal 
cortex to 9.6 in cerebellum (Supplementary Table 1). Regional values of two-tissue mean VT 
(mL∙cm-3) for [11C]FPEB ranged from 17 in temporal cortex to 6.7 in cerebellum 
(Supplementary Table 2). All the rate constants (K1, k2, k3, and k4) were relatively well-identified 
with an average SE of less than ~20% across all regions (Supplementary Tables 3 and 4). 
 With regard to the second result, we first used large regional values to calculate VT with 
the Logan and MA1 methods and confirmed that these two mathematically simple methods gave 
VT values almost identical to those obtained by more complex compartmental modeling. We then 
applied Logan and MA1 methods to voxel data. The voxel-based Logan model (Loganvoxel) 
significantly underestimated VT compared to the two-tissue compartment model with a mean 
difference of 10% for [
11
C]FPEB and 15% for [
11
C]SP203. Voxel-based MA1 gave VT values 
almost identical to those obtained via two-tissue compartment modeling for VOI data with a 
mean difference of 6% for [
11
C]FPEB and 4% for [
11
C]SP203 (Supplementary Tables 1 and 2). 
Further, MA1voxel VT and two-tissue VT showed excellent correlation (p<0.0001) across brain 
regions from all subjects for both radiotracers, with a regression slope close to one and a small 
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intercept (Supplementary Figs. 3A and 3B). In addition, the parametric images were of high 
quality, with excellent contrast between gray and white matter; few voxels had unrealistically 
high or low VT values (Fig. 3). Therefore, voxel-based MA1 appeared to be a valid method for 
measuring mGluR5s at the voxel level. 
 As regards the third result, and to determine the minimum scanning time needed to 
accurately measure VT, we increasingly truncated the entire scan in 10-minute increments from 
0–120 to 0–30 minutes. For [11C]FPEB, the increase in VT was less than 5% during the last hour 
of the two-hour scan, with stable values as early as 80 minutes (Fig. 4A); this indicates negligible 
accumulation of radiometabolites and suggests that 80 minutes of scan data are adequate to 
calculate VT. In contrast, VT values for [
11
C]SP203 gradually increased by about 10% during the 
last hour of the two-hour scan and showed a rising trend without reaching a stable value (Fig. 
4B). We had previously found that VT values for [
18
F]SP203 also increased by about 10% during 
the same period.
3
 Similar increments with [
11
C]SP203 indicate that the radiometabolite (possibly 
glutathionylated conjugate) could be accumulating in the brain.  
 
Genomic plot 
Regional values for the mGluR5 gene transcript were highly correlated with those of PET 
VT for both tracers (for [
11
C]FPEB, Pearson’s R2=0.72, p<0.01, two-tailed; for [11C]SP203 
Pearson’s R2=0.76, p<0.01, two-tailed), supporting the use of the genomic plot for VND 
quantification. This high correlation was predominantly driven by the cerebellum, which is 
characterized by both low mRNA expression and low PET binding. Notably, brain mRNA 
expression for mGluR5 was highly consistent across all donors of the Allen Human Brain atlas 
(Pearson's R
2
: 0.925±0.033). 
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Following genomic plot application (Fig. 5), the estimated VND was 2.7 mL·cm
-3
 for 
[
11
C]FPEB and 4.3 mL·cm
-3
 for [
11
C]SP203. The resulting binding potential estimates were 
highly comparable (Pearson’s r=0.99, p<0.001). The highest binding was found in the temporal 
cortex ([
11
C]FPEB BPND=5.3; [
11
C]SP203 BPND=5.1), followed by cingulate cortex ([
11
C]FPEB 
BPND=4.7; [
11
C]SP203 BPND=4.9). For both tracers, a significant amount of specific binding was 
found in the cerebellum, as BPND was 1.4 for [
11
C]FPEB and 1.2 for [
11
C]SP203. Because BPND 
is the ratio at equilibrium of specific to nondisplaceable uptake, these values imply that about 
60% of total cerebellar uptake was specifically bound to mGluR5. 
 
Whole-body Biodistribution and Dosimetry Estimates 
 Whole-body images were notable for early distribution of radioactivity in the blood pool, 
accumulation in the target organ (i.e., brain), and excretion via hepatobiliary and urinary routes 
(Supplementary Figs. 4 and 5). At early time points, radioactivity was prominent in organs with 
high blood volume, including liver, kidneys, and brain. Consistent with its high densities of 
mGluR5, high radioactivity uptake was observed in brain, with a peak of 11-12% of injected 
activity 5-10 minutes after [
11
C]FPEB or [
11
C]SP203 injection. [
11
C]SP203 radioactivity was 
excreted via both hepatobiliary and urinary routes, with 9% of the injected activity in gallbladder, 
8% in small intestine, and 19% in urinary bladder by the end of the scan. [
11
C]FPEB 
radioactivity was also excreted via both hepatobiliary and urinary routes, with 4.5% of the 
injected activity in liver, 8% in gallbladder, and 11% in urinary bladder by the end of the scan 
(Supplementary Fig. 6). Lumbar vertebrae were visible in the scans. 
 For [
11
C]FPEB, the three source organs with the highest time-integrated activity 
coefficients were liver, brain, and urinary bladder; for [
11
C]SP203, the organs were liver, brain, 
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and red marrow (Supplementary Table 5). The three organs with the highest radiation-absorbed-
doses (Sv/MBq) for [11C]FPEB were gallbladder wall (41.2±20.5), urinary bladder wall 
(14.3±3.8), and brain (12.2±2.0); for [
11
C]SP203, the organs were gallbladder wall (38.1±27.7), 
urinary bladder wall (17.1±5.4), and kidneys (12.0±3.0) (Supplementary Table 6). The effective 
dose, a weighted sum of overall exposure to the body, was 3.7±0.2 µSv/MBq for [
11
C]FPEB and 
4.4±0.4 µSv/MBq for [
11
C]SP203. 
 
Discussion 
This study sought to compare the ability of two 
11
C-labeled radioligands to quantify 
mGluR5 in human brain, to determine whether radiometabolites accumulate in brain, and to 
determine if cerebellum has specific binding to mGluR5. We found that both [
11
C]FPEB and 
[
11
C]SP203 effectively quantified regional mGluR5 distribution in human brain. However, 
[
11
C]FPEB was the superior radioligand because [
11
C]SP203, like its 
18
F version, generated 
radiometabolites that accumulate in brain, as evidenced by increasing values of apparent VT over 
the course of the scan. The genomic plot suggested that about 60% of cerebellar uptake for both 
radioligands reflected specific binding to mGluR5. As a secondary aim of this study, we also 
calculated the radiation dosimetry of [
11
C]FPEB and [
11
C]SP203 and found that their effective 
doses (ED) were low (~4 µSv/MBq) and similar to other 
11
C-labeled PET radioligands.
27
 
Using region and voxel-wise kinetic modeling approaches, mGluR5 was quantified in 
terms of VT for both [
11
C]FPEB and [
11
C]SP203. Both tracers yielded well identifiable VT values 
that were consistent with regional mGluR5 distribution in human brain (Supplementary Tables 1 
and 2). However, the apparent VT of [
11
C]FPEB was more stable over time than that of 
[
11
C]SP203 (Fig. 4), consistent with the ability of [
11
C]FPEB to generate few radiometabolites 
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that accumulate in brain (Fig. 4). With regard to [
11
C]SP203, which is known to undergo 
glutathionylation, the expectation that any glutathionylated metabolite generated will be expelled 
from brain did not appear to occur. Thus, it is unlikely that SP203 will be useful. Instead, we 
recommend FPEB for effective quantification of mGluR5. 
 
Low Specific Activity of [
11
C]FPEB and [
11
C]SP203 
The specific activity of the two radioligands was relatively low at the time of injection: ~ 
20 GBq/µmol for [
11
C]FPEB and ~ 40 GBq/µmol for [
11
C]SP203 (Table 1). The carrier in these 
low specific activity radioligands likely led to significant receptor occupancy, thereby causing 
our VT values to be lower than those using the 
18
F-labeled versions, whose specific activity was 
~150-300 GBq/µmol (Table 1). We estimated receptor occupancies at the time of peak specific 
brain uptake, based on published values of receptor density (Bmax)
26
 (Table 2). The peak 
concentration of specific binding was determined from two-compartment modeling, which 
separately estimates concentration in the specific and nondisplaceable compartments. Occupancy 
of the receptor by carrier (i.e., nonradioactive parent radioligand) ranged from 4% for 
[
11
C]SP203 in frontal cortex to 27% for [
11
C]FPEB in cerebellum. The estimates for almost all 
regions was >5%, which is often regarded as a limit for a true tracer dose of radioligand. The 
resulting self-blockade would decrease our measured values of VT, which was apparent relative 
to the 
18
F-labeled radioligands that have higher specific activity (Table 1). A major limitation of 
our estimates of receptor occupancy is that we do not know the density of mGluR5s in vivo that 
are available to bind radioligand – i.e., Bavail.  Instead, we used the in vitro measurement of 
receptor density (Bmax), for which we found only one published value in human brain
26
. However, 
only a subset of receptors measured in vitro in homogenized tissue may be in the proper location 
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or conjoined with other proteins to be able to bind radiolabeled drug in vivo. True measurements 
of in vivo receptor occupancy require baseline and partially blocked scans, which can then be 
analyzed with the so-called Lassen / occupancy plot
28
. 
The cause of the low specific activity of the radioligands was the low specific activity of 
the [
11
C]hydrogen cyanide used as the labeling agent. In this study [
11
C]hydrogen cyanide was 
prepared from cyclotron-produced [
11
C]carbon dioxide.
25 
Improved specific activity may be 
obtainable by using [
11
C]hydrogen cyanide produced from cyclotron-produced [
11
C]methane
29
 
rather than from [
11
C]carbon dioxide. 
 
Genomic Plot 
Here, we used the genomic variant of the Lassen plot to estimate the specific and 
nondisplaceable components of both radioligands, a task that would otherwise require 
administration of blocking doses of a non-radioactive drug. The method is generally applicable 
to any protein PET target that shows good correlation of regional densities of gene transcript 
from a genomic atlas with the density of expressed protein measured with PET.
9
 In fact, both 
[
11
C]FPEB and [
11
C]SP203 showed high correlations among brain regions between mGluR5 
mRNA expression and the VT estimates (R
2
=0.72 and 0.76, respectively) (Fig. 5). A similar 
correlation can be obtained using the [
18
F]FPEB VT regional estimates published by Sullivan and 
colleagues (R
2
=0.67).
1
  
The genomic plot for mGluR5 had two major results. First, both [
11
C]FPEB and 
[
11
C]SP203 provided a high percentage of specific binding in human brain. For example, in the 
highest density region—the temporal cortex—specific binding (VS) of both radioligands was 
84% of total uptake VT (Supplementary Tables 1 and 2), assuming VND is 2.7 mL·cm
-3
 for 
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[
11
C]FPEB and 4.3 mL·cm
-3
 for [
11
C]SP203. Second, even the lowest density region, the 
cerebellum, had a high percentage (~60%) of specific binding. This finding is consistent with 
that for another mGluR5 radioligand, [
11
C]AZD9272, but that study required administration of 
an mGluR5 blocking drug
30
. Taken together, the data indicate that the cerebellum is not a 
suitable reference region—i.e., one that lacks specific binding. Furthermore, if the cerebellum 
were going to be used as a pseudo-reference region (i.e., one with low specific binding), it must 
be shown to be similar between patient and control groups.
31, 32
 
 
Conclusion  
Results from both prior studies using the 
18
F-labeled versions and the current study, 
which used 
11
C-labeled versions, indicate that FPEB is superior to SP203 as a ligand for 
quantifying mGluR5. The major advantage of FPEB is that its VT, a measure of receptor density, 
is quite stable after 60 to 90 minutes of imaging, consistent with it generating minimal 
radiometabolites that accumulate in brain. Because stable values are achieved within the 
practical imaging time for 
11
C (T1/2 = 20 min), [
11
C]FPEB could be used for multiple studies in a 
single subject within one day; this would, however, require higher specific activity than was 
achieved in this study. 
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Figure Legends 
 
Fig. 1 The structure of SP203 and its radiometabolites showing different labeling positions for 
18
F and 
11
C, and the different metabolism by glutathione S-transferase.  
 
Fig. 2 Radioactivity concentrations, parent radioligand fraction in plasma, and brain time activity 
curves from a representative subject injected with [
11
C]FPEB (A – C) or [11C]SP203 (D – F). 
The first panels (A and D) for each radioligand plot the concentration of parent radioligand, 
separated from radiometabolites as a function of time after injection. The middle panels (B and 
E) show the percentage of total radioactivity in plasma that represents parent radioligand. The 
last panels (C and F) plot the concentrations of radioactivity in three brain regions as a function 
of time after injection. The lines represent the unconstrained two-tissue compartment model that 
well fit all data points. (o)–putamen, (●)–thalamus, and (□)–cerebellum. 
 
Fig. 3 PET and MR images in axial (left), sagittal (middle), and coronal (right) views. Top row: 
Parametric MA1 PET images of a 25-year old healthy male injected with 730 MBq of 
[
11
C]FPEB and 2 h scan duration. Middle row: Parametric MA1 PET images of a 23-year old 
healthy female injected with 670 MBq [
11
C]SP203 and 2 h scan duration. Bottom row: MR 
images of the same subject scanned with [
11
C]FPEB. Each voxel in the PET images represents 
distribution volume (VT), with its value encoded in the color scale on right. 
 
Fig. 4 Distribution volume (VT) as a function of duration of image acquisition for [
11
C]FPEB (A) 
and [
11
C]SP203 (B). VT was calculated for cerebellum (●) using an unconstrained two-tissue 
compartment model with increasingly truncated acquisition times. Values are normalized as 
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percentage of terminal value attained from 120 minutes of imaging. Data represent mean ± SD of 
eight subjects for [
11
C]FPEB and six subjects for [
11
C]SP203. 
 
Fig. 5 Genomic plots of eight brain regions for [
11
C]FPEB (A) and [
11
C]SP203 (B). The y-axis is 
the gene expression for human mGluR5 from the Allen Brain Atlas and its density is expressed 
relative to expression of housekeeping gene. Data points (●) represent mean values, with 
standard error bars shown for both x and y values. The linear regressions shows an x-intercept (= 
VND) of 2.7 mL·cm
-3
 for [
11
C]FPEB and 4.3 mL·cm
-3
 for [
11
C]SP203. 
  
Tables 
Table 1. Comparison of distribution volume (V
T
), plasma free fraction (f
P
), and related parameters among mGluR5 radioligands used 
in human brain 
 
PET ligand [11C]FPEB   [18F]FPEB  [18F]FPEB  [18F]SP203   [11C]SP203   
 Reference 
(Current 
study) 
1  2   3 
(Current  
study) 
V
T
 values * 10 – 17 17 – 32  14 – 26   15 – 26  17 – 26  
V
T
 (Cerebellum)  6.7 10 – 14 10 
Test-retest variability  
– – ~20% (VT)       – – 
  ~10% (BPND)     
Plasma free fraction 
 (f
P
)  
6.3 ± 0.8%      4.7 ± 0.6% 8.1 ± 0.7% 5.2 ± 0.2%    2.8 ± 0.1% 
   4.3 ± 0.7%  
     
V
T
 /fP (Thalamus) 148 362 173 – 653 
Specific activity at TOI 
(GBq/µmol) 
22 ± 6 144 ± 44 330 ± 210 156 ± 54 40 ± 6 
Injected mass dose (µg) 7.4 ± 1.5 0.3 ± 0.1 0.10 ± 0.06 0.6 ± 0.2 4.3 ± 0.9 
 
* Regional VT values except for cerebellum. TOI: Time of injection. The VT/fP values were calculated by dividing 
average VT for thalamus with average fp values for each PET ligand from the current and reported studies. 
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Table 2. Receptor occupancies achieved by [
11
C]FPEB and [
11
C]SP203 at time of peak specific binding in three brain regions.  
Brain 
region 
mGluR5 
Bmax (nM)
1
 
Peak brain concentration 
(nM) 
% Occupancy at peak brain 
concentration
 
Peak specific brain 
concentration (nM)
2
 
% Occupancy at peak 
specific brain 
concentration
3 
[
11
C]FPEB [
11
C]SP203 [
11
C]FPEB [
11
C]SP203 [
11
C]FPEB [
11
C]SP203 [
11
C]FPEB [
11
C]SP203 
Frontal 
cortex 25 ± 5.6 3.4 ± 1.0 1.2 ± 0.3 13 ± 4.1 4.9 ± 1.4 3.0 ± 1.0 1.1 ± 0.4 12 ± 3.9 4.2 ± 1.4 
Caudate 17 ± 2.3 3.1 ± 1.0 1.2 ± 0.3 18 ± 5.6 7.0 ± 2.0 2.6 ± 1.0 1.0 ± 0.3 15 ± 5.7 5.8 ± 2.0 
Cerebellum 5.1 ± 2.0 2.8 ± 0.9 1.0 ± 0.3 55 ± 17 19 ± 5.9 1.4 ± 0.5 0.5 ± 0.2 27 ± 10 10 ± 3.0 
Data are mean ± SD from eight subjects for [
11
C]FPEB and six subjects for [
11
C]SP203. 
1
Bmax values are from Patel et al., Nucl Med Biol 2007
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 and assume that 10 mg brain contains 1 mg protein. 
2
The concentration of specific binding came from the two-tissue compartment model, which separates radioligand into specific and 
nondisplaceable compartments. 
3
Occupancy for each region was calculated by dividing peak specific concentration by its Bmax. 
